Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland

no Abstract.

[1]  J. Bussel,et al.  Romiplostim use in pregnant women with immune thrombocytopenia , 2022, American journal of hematology.

[2]  P. Saluja,et al.  A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19 Vaccination , 2022, Vaccines.

[3]  J. Bussel,et al.  A narrative review of anti-SARS-CoV-2 vaccines and immune thrombocytopenia: be aware, but reassured. , 2022, Clinical advances in hematology & oncology : H&O.

[4]  Yanfeng Liu,et al.  Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. , 2022, Blood.

[5]  K. Samii,et al.  Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report , 2022, Thrombosis Journal.

[6]  D. Kuter,et al.  Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia , 2022, Blood advances.

[7]  S. Szmit,et al.  EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer , 2022, HemaSphere.

[8]  C. D. Packer,et al.  Persistent Relapsing Immune Thrombocytopenia Following COVID-19 Infection , 2022, Cureus.

[9]  C. Bradbury,et al.  Incidence of adult primary immune thrombocytopenia in England—An update , 2022, European journal of haematology.

[10]  Bjoern Peters,et al.  Bioinformatic Analysis Underpinning the Frequent Occurrence of Immune Thrombocytopenic Purpura in COVID-19 Patients. , 2022, The Israel Medical Association journal : IMAJ.

[11]  J. C. Callejas Rubio,et al.  Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia , 2022, Medicina Clínica (English Edition).

[12]  D. Gómez-Almaguer,et al.  Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature , 2022, Journal of Thrombosis and Thrombolysis.

[13]  Dolca Thomas,et al.  Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. , 2022, The New England journal of medicine.

[14]  Elias B Rizk,et al.  Immune Thrombocytopenic Purpura and Intracerebral Hemorrhage, Incidence, and Mortality , 2022, Cureus.

[15]  G. Moulis,et al.  De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring , 2022, Blood.

[16]  J. Bussel,et al.  SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP , 2022, Blood.

[17]  Abdel-Naser Elzouki,et al.  Gestational Thrombocytopenia: A Review on Recent Updates , 2022, Cureus.

[18]  F. Buccisano,et al.  Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives , 2022, Annals of Hematology.

[19]  H. Al‐Samkari,et al.  Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study , 2022, British journal of haematology.

[20]  Shaoyan Hu,et al.  Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis , 2022, Annals of Hematology.

[21]  F. Cottone,et al.  Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy , 2022, Annals of Hematology.

[22]  T. Rakza,et al.  Risk factors for severe neonatal thrombocytopenia in cases of maternal immune thrombocytopenia , 2022, Acta paediatrica.

[23]  Qianqian Wang,et al.  Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study , 2022, Therapeutic advances in hematology.

[24]  N. Warren,et al.  Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives , 2022, Open access emergency medicine : OAEM.

[25]  E. van Werkhoven,et al.  COVID-19 vaccination in patients with immune thrombocytopenia , 2021, Blood Advances.

[26]  M. Voigtlaender,et al.  Management of Vascular Thrombosis in Patients with Thrombocytopenia , 2021, Hämostaseologie.

[27]  Aaron C Petrey,et al.  Platelet Dysregulation in the Pathobiology of COVID-19 , 2021, Hämostaseologie.

[28]  Z. Pravdic,et al.  Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges. , 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  T. Tvedt,et al.  PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY) , 2021, HemaSphere.

[30]  Hao Jiang,et al.  Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020) , 2021, Blood.

[31]  G. Leverger,et al.  Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry , 2021, Blood.

[32]  M. Hou,et al.  Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP) , 2021, Blood.

[33]  Hao Jiang,et al.  All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. , 2021, Blood.

[34]  B. Bonnotte,et al.  Splenectomy for Primary Immune Thrombocytopenia revisited in the era of Thrombopoietin Receptor Agonists: new insights for an old treatment. , 2021, American journal of hematology.

[35]  M. Mingot-Castellano.  New treatments for primary immune thrombocytopenia , 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[36]  A. Enjeti,et al.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand , 2021, The Medical journal of Australia.

[37]  Xiao-hui Zhang,et al.  All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. , 2021, The Lancet. Haematology.

[38]  Adrienne M K Landsteiner,et al.  Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis , 2021, Annals of Hematology.

[39]  C. Bradbury,et al.  Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. , 2021, The New England journal of medicine.

[40]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[41]  Yahiya Y. Syed.  Hetrombopag: First Approval , 2021, Drugs.

[42]  É. Oksenhendler,et al.  Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. , 2021, Haematologica.

[43]  J. Di Paola,et al.  Diagnostic approach to the patient with a suspected inherited platelet disorder: Who and how to test , 2021, Journal of thrombosis and haemostasis : JTH.

[44]  H. Liebman,et al.  Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern , 2021, Research and practice in thrombosis and haemostasis.

[45]  G. Guyatt,et al.  Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology , 2021, Journal of thrombosis and haemostasis : JTH.

[46]  J. Qian,et al.  Atorvastatin improves bone marrow endothelial progenitor cell function from patients with immune-related hemocytopenia , 2021, Annals of translational medicine.

[47]  S. de Lusignan,et al.  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland , 2021, Nature Medicine.

[48]  J. Kelton,et al.  Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria , 2021, British journal of haematology.

[49]  B. Bonnotte,et al.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments , 2021, HemaSphere.

[50]  A. Josting,et al.  Treatment of immune thrombocytopenia (ITP) with Eltrombopag – results of the 3 rd interim analysis of the German non-interventional trial RISA. Focussing on steroid-pretreatment and fatigue , 2021, Hämostaseologie.

[51]  D. Kuter.  Exacerbation of immune thrombocytopenia following COVID‐19 vaccination , 2021, British journal of haematology.

[52]  Yanfeng Liu,et al.  Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia , 2021, British journal of haematology.

[53]  Ravi Goud,et al.  Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS) , 2021, Vaccine.

[54]  Xiang Hu,et al.  Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia , 2021, Blood.

[55]  Eun-Ju Lee,et al.  Immune thrombocytopenia during the COVID‐19 pandemic , 2021, British journal of haematology.

[56]  D. Kuter,et al.  How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. , 2021, Blood.

[57]  Dawn Swan,et al.  Thrombosis in immune thrombocytopenia — current status and future perspectives , 2021, British journal of haematology.

[58]  R. Scharf.  Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management , 2021, Journal of clinical medicine.

[59]  C. Neunert.  Looking long-term: an unmet need in immune thrombocytopenia. , 2021, The Lancet. Haematology.

[60]  Hong-guo Zhao,et al.  Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. , 2021, The Lancet. Haematology.

[61]  Clóvis Paniz,et al.  Diagnostic characteristics of immature platelet fraction for the assessment of immune thrombocytopenia. , 2021, Thrombosis research.

[62]  S. Holzhauer,et al.  Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. , 2021, Blood advances.

[63]  C. Kruse,et al.  Immune thrombocytopenia: the patient’s perspective , 2021, Annals of Blood.

[64]  U. Dianzani,et al.  Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study , 2021, British journal of haematology.

[65]  Eun-Ju Lee,et al.  Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination , 2021, American journal of hematology.

[66]  T. Langerak,et al.  Thrombocytopenia in Virus Infections , 2021, Journal of clinical medicine.

[67]  C. Ritter.  Arzneimittelinteraktionen zwischen oralen TKI und pflanzlichen Präparaten , 2021, InFo Hämatologie + Onkologie.

[68]  H. Richter,et al.  Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany , 2021, Hematology.

[69]  M. Broder,et al.  Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method , 2020, Research and practice in thrombosis and haemostasis.

[70]  P. Giordano,et al.  Fatigue perception in a cohort of children with chronic immune thrombocytopenia and their caregivers using the PedsQL MFS: Real‐life multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) , 2020, Pediatric blood & cancer.

[71]  F. Nimmerjahn,et al.  A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP) , 2020, Hämostaseologie.

[72]  C. Haioun,et al.  Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study , 2020 .

[73]  B. Shah,et al.  Efficacy and Safety of Biosimilar Romiplostim in Immune Thrombocytopenic Purpura : Single Centre Retrospective Data Analysis , 2020 .

[74]  J. Lega,et al.  Les purpuras thrombopéniques immunologiques secondaires de l’adulte , 2020 .

[75]  J. Bussel,et al.  Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life , 2020, American journal of hematology.

[76]  J. González-Porras,et al.  A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. , 2020, Blood cells, molecules & diseases.

[77]  S. Bahmanyar,et al.  Cancer risk in patients with primary immune thrombocytopenia - A Swedish nationwide register study. , 2020, Cancer epidemiology.

[78]  V. Jiménez‐Yuste,et al.  Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia , 2020, British journal of haematology.

[79]  J. Bussel,et al.  Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. , 2020, Blood advances.

[80]  Hong-guo Zhao,et al.  High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial , 2020, American journal of hematology.

[81]  J. Semple,et al.  An update on the pathophysiology of immune thrombocytopenia , 2020, Current opinion in hematology.

[82]  T. Tvedt,et al.  Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. , 2020, Blood.

[83]  Fangyingnan Zhang,et al.  Immature platelet fraction related parameters in the differential diagnosis of thrombocytopenia , 2020, Platelets.

[84]  D. Sharp,et al.  IDENTIFICATION OF OCCULT CEREBRAL MICROBLEEDS IN ADULTS WITH IMMUNE THROMBOCYTOPENIA. , 2020, Blood.

[85]  C. Bradbury,et al.  Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel , 2020, Acta Haematologica.

[86]  U. Platzbecker,et al.  Disease management of patients with immune thrombocytopenia—results of a representative retrospective survey in Germany , 2020, Annals of Hematology.

[87]  J. Bussel,et al.  Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia , 2020, British journal of haematology.

[88]  E. Andrès,et al.  Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series , 2020, British journal of haematology.

[89]  R. Kapur.  Fine‐tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second‐line therapy , 2020, British journal of haematology.

[90]  M. Lambert,et al.  Racial Variation in ITP Prevalence and Chronic Disease Phenotype Suggests Biological Differences. , 2020, Blood.

[91]  W. Ageno,et al.  Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection , 2020, Annals of Hematology.

[92]  M. Cicardi,et al.  Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. , 2020, Clinical and Experimental Immunology.

[93]  M. Yue,et al.  The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis , 2020, BioMed research international.

[94]  J. Bussel,et al.  Fatigue in children and adolescents with immune thrombocytopenia , 2020, British journal of haematology.

[95]  F. Carrier,et al.  Severe immune thrombocytopenic purpura in critical COVID-19 , 2020, International Journal of Hematology.

[96]  F. Leebeek,et al.  COVID‐19‐associated immune thrombocytopenia , 2020, British journal of haematology.

[97]  M. Brookhart,et al.  Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States , 2020, Clinical epidemiology.

[98]  J. Ewing,et al.  Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review , 2020, British journal of haematology.

[99]  A. Matzdorff,et al.  Immunthrombozytopenie (ITP) und andere Thrombozytopenien in der Schwangerschaft , 2020, Transfusionsmedizin - Immunhämatologie · Hämotherapie · Transplantationsimmunologie · Zelltherapie.

[100]  A. Waage,et al.  Long‐term outcomes of patients treated with rituximab as second‐line treatment for adult immune thrombocytopenia – Follow‐up of the RITP study , 2020, British journal of haematology.

[101]  Yuan Yu,et al.  Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[102]  Qi Zhou,et al.  Mechanism of thrombocytopenia in COVID-19 patients , 2020, Annals of Hematology.

[103]  Hao Zhou,et al.  Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19) , 2020, medRxiv.

[104]  E. Andrès,et al.  Immune Thrombocytopenic Purpura in a Patient with Covid-19 , 2020, The New England journal of medicine.

[105]  Y. Oymak,et al.  Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey , 2020, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[106]  H. Al‐Samkari,et al.  A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. , 2020, Blood advances.

[107]  Xin Du,et al.  Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia , 2020, British journal of haematology.

[108]  Y. Tomiyama,et al.  Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision , 2020, International Journal of Hematology.

[109]  H. Al‐Samkari,et al.  Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment , 2019, Seminars in Thrombosis and Hemostasis.

[110]  S. Vesely,et al.  American Society of Hematology 2019 guidelines for immune thrombocytopenia. , 2019, Blood advances.

[111]  C. Santoro,et al.  Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. , 2019, Blood reviews.

[112]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[113]  J. Bussel,et al.  Identifying and Treating Refractory ITP: Difficulty in Diagnosis and Role of Combination Treatment. , 2019, Blood.

[114]  H. Al‐Samkari,et al.  Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features , 2019, Research and practice in thrombosis and haemostasis.

[115]  H. de Haard,et al.  Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia , 2019, American journal of hematology.

[116]  Xin Wang,et al.  A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia , 2019, American journal of hematology.

[117]  H. Sørensen,et al.  Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim , 2019, EClinicalMedicine.

[118]  A. Greinacher,et al.  Simplifying the diagnosis of inherited platelet disorders? The new tools do not make it any easier. , 2019, Blood.

[119]  J. Bussel,et al.  PF712 PHYSICIANS’ PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) , 2019, HemaSphere.

[120]  J. Kanis,et al.  The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper , 2019, British journal of haematology.

[121]  U. Sachs.  Diagnosing Immune Thrombocytopenia , 2019, Hämostaseologie.

[122]  Chunhong Ma,et al.  Proteasome Inhibition with Bortezomib Induces Apoptosis of Long-Lived Plasma Cells in Steroid-Resistant or Relapsed Immune Thrombocytopaenia , 2018, Thrombosis and Haemostasis.

[123]  O. Meyer,et al.  Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH, GPOH und DGTI , 2018, Oncology Research and Treatment.

[124]  C. Neunert.  Management of newly diagnosed immune thrombocytopenia: can we change outcomes? , 2017, Hematology. American Society of Hematology. Education Program.

[125]  J. Kelton,et al.  Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. , 2017, Blood advances.

[126]  Dionne A. Graham,et al.  Increasing observation rates in low‐risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP®) , 2017, Pediatric Blood & Cancer.

[127]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[128]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[129]  H. Fineberg,et al.  Antibody Depletion by Bortezomib through Blocking of Antigen Presentation , 2013 .

[130]  Asplenie und Hyposplenismus.  Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie , 2013, Kinder- und Jugendmedizin.